Catalent Invests $200 Million to Expand Biologics Capacity and Capabilities
January 07 2019 - 7:00AM
Business Wire
Catalent, Inc. (NYSE:CTLT), the leading global provider of
advanced delivery technologies and development solutions for drugs,
biologics and consumer health products, today announced it has
commenced a $200 million capital investment in its Biologics
business to expand drug substance manufacturing capacity and drug
product fill/finish capacity due to projected growth among existing
and future customers. The investments, phased over a three-year
program, will be undertaken at the company’s biologics
manufacturing sites in Madison, Wisconsin and Bloomington, Indiana.
This follows a recent announcement to invest $14 million in
packaging capabilities at the Bloomington site.
Mammalian cell culture capacity will be increased at Madison
with the build out of two new suites, each with a 2 x 2,000 liter
single-use bioreactor system, providing additional clinical and
commercial production capacity at the 2,000 or 4,000-liter batch
scale. Work is expected to be completed by mid-2021 and will more
than double Catalent’s commercial biomanufacturing capacity.
Additionally, fill/finish capacity at the Bloomington site will
be expanded by 79,000 sq. ft., with both GMP and non-GMP
capabilities. A high-speed flexible vial line, utilizing both
ready-to-use (RTU) components and bulk filling, at a filling speed
of 300 units per minute, will be installed along with a high-speed
flexible syringe/cartridge line with a filling speed of over 300
units per minute, and a fully automated vial inspection
machine.
“The expansions at both sites will support our customers’
development programs and commercial launches,” commented Barry
Littlejohns, President, Catalent Biologics and Specialty Drug
Delivery. He added, “Catalent’s continued investments in innovative
technologies and flexible capacity allow us to offer the most
comprehensive solutions to bring important and innovative
treatments to market faster.”
Opened in April 2013 and recently expanded with the addition of
a 2 x 2,000-liter single-use bioreactor suite and new laboratories,
Catalent Biologics’ Madison facility specializes in development,
manufacturing and analytical services for new biological entities
and biosimilars. It is the home of the company’s proprietary GPEx®
cell line development technology, used to create high-yielding
mammalian cell lines. This year, Catalent celebrated a significant
milestone when the tenth biologic therapy utilizing GPEx technology
was approved for commercial use. The Madison facility was designed
for cGMP production from 10 to 4,000-liter scale, providing
flexibility in batch size to meet client needs.
Catalent’s 875,000-square-foot biologics development and
manufacturing facility in Bloomington employs a growing staff of
900 employees, with deep expertise in sterile formulation and
extensive biomanufacturing and drug product fill/finish capacity
across liquid and lyophilized vials, prefilled syringes, and
cartridges. The site also recently achieved regulatory approval for
a twentieth commercial product.
About Catalent Biologics
Catalent Biologics provides advanced technologies and tailored
solutions for biologic and biosimilar development, from DNA to
commercial supply, through our extensive Biologics network
including: Madison, Wisconsin; Emeryville, California; Kansas City,
Missouri; Morrisville, North Carolina, Bloomington, Indiana; and
Brussels, Belgium. For more information on Catalent Biologics,
visit www.catalent.com/biologics.
About Catalent, Inc.
Catalent is the leading global provider of advanced delivery
technologies and development solutions for drugs, biologics and
consumer health products. With 85 years serving the industry,
Catalent has proven expertise in bringing more customer products to
market faster, enhancing product performance and ensuring reliable
clinical and commercial product supply. Catalent employs over
11,000 people, including over 1,800 scientists, at more than 30
facilities across five continents, and in fiscal 2018 generated
approximately $2.5 billion in annual revenue. Catalent is
headquartered in Somerset, New Jersey. For more information, visit
www.catalent.com.
More products. Better treatments. Reliably supplied.™
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190107005114/en/
Investor Contact:
Thomas CastellanoCatalent, Inc.(732)
537-6325investors@catalent.com
Media Contacts:
Chris Halling+44 (0)7580 041073chris.halling@catalent.com
Richard Kerns+44 (0)161 728 5880richard@nepr.eu
Catalent (NYSE:CTLT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalent (NYSE:CTLT)
Historical Stock Chart
From Apr 2023 to Apr 2024